These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

640 related articles for article (PubMed ID: 33450361)

  • 1. Anti-PD-(L)1 immunotherapy for brain metastases in non-small cell lung cancer: Mechanisms, advances, and challenges.
    Zhou S; Xie J; Huang Z; Deng L; Wu L; Yu J; Meng X
    Cancer Lett; 2021 Apr; 502():166-179. PubMed ID: 33450361
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunotherapy in NSCLC patients with brain metastases. Understanding brain tumor microenvironment and dissecting outcomes from immune checkpoint blockade in the clinic.
    Vilariño N; Bruna J; Bosch-Barrera J; Valiente M; Nadal E
    Cancer Treat Rev; 2020 Sep; 89():102067. PubMed ID: 32682248
    [TBL] [Abstract][Full Text] [Related]  

  • 3. PD-1/PD-L1 Blockade Therapy in Advanced Non-Small-Cell Lung Cancer: Current Status and Future Directions.
    Xia L; Liu Y; Wang Y
    Oncologist; 2019 Feb; 24(Suppl 1):S31-S41. PubMed ID: 30819829
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy of PD-1/L1 inhibitors in brain metastases of non-small-cell lung cancer: pooled analysis from seven randomized controlled trials.
    Li W; Jiang J; Huang L; Long F
    Future Oncol; 2022 Jan; 18(3):403-412. PubMed ID: 34787500
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combination Therapy of Radiotherapy and Anti-PD-1/PD-L1 Treatment in Non-Small-cell Lung Cancer: A Mini-review.
    Takamori S; Toyokawa G; Takada K; Shoji F; Okamoto T; Maehara Y
    Clin Lung Cancer; 2018 Jan; 19(1):12-16. PubMed ID: 28739315
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The next generation of immunotherapy: keeping lung cancer in check.
    Somasundaram A; Burns TF
    J Hematol Oncol; 2017 Apr; 10(1):87. PubMed ID: 28434399
    [TBL] [Abstract][Full Text] [Related]  

  • 7. SBRT combined with PD-1/PD-L1 inhibitors in NSCLC treatment: a focus on the mechanisms, advances, and future challenges.
    Chen Y; Gao M; Huang Z; Yu J; Meng X
    J Hematol Oncol; 2020 Jul; 13(1):105. PubMed ID: 32723363
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The superior efficacy of anti-PD-1/PD-L1 immunotherapy in KRAS-mutant non-small cell lung cancer that correlates with an inflammatory phenotype and increased immunogenicity.
    Liu C; Zheng S; Jin R; Wang X; Wang F; Zang R; Xu H; Lu Z; Huang J; Lei Y; Mao S; Wang Y; Feng X; Sun N; Wang Y; He J
    Cancer Lett; 2020 Feb; 470():95-105. PubMed ID: 31644929
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Which is the optimal immunotherapy for advanced squamous non-small-cell lung cancer in combination with chemotherapy: anti-PD-1 or anti-PD-L1?
    Zhang Y; Zhou H; Zhang L
    J Immunother Cancer; 2018 Dec; 6(1):135. PubMed ID: 30509312
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy of Immune Checkpoint Inhibitors in KRAS-Mutant Non-Small Cell Lung Cancer (NSCLC).
    Jeanson A; Tomasini P; Souquet-Bressand M; Brandone N; Boucekine M; Grangeon M; Chaleat S; Khobta N; Milia J; Mhanna L; Greillier L; Biemar J; Nanni I; Ouafik L; Garcia S; Mazières J; Barlesi F; Mascaux C
    J Thorac Oncol; 2019 Jun; 14(6):1095-1101. PubMed ID: 30738221
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Switching administration of anti-PD-1 and anti-PD-L1 antibodies as immune checkpoint inhibitor rechallenge in individuals with advanced non-small cell lung cancer: Case series and literature review.
    Kitagawa S; Hakozaki T; Kitadai R; Hosomi Y
    Thorac Cancer; 2020 Jul; 11(7):1927-1933. PubMed ID: 32421224
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pembrolizumab in the treatment of metastatic non-small cell lung cancer: a review of current evidence.
    Rihawi K; Gelsomino F; Sperandi F; Melotti B; Fiorentino M; Casolari L; Ardizzoni A
    Ther Adv Respir Dis; 2017 Sep; 11(9):353-373. PubMed ID: 28818019
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer.
    Herzberg B; Campo MJ; Gainor JF
    Oncologist; 2017 Jan; 22(1):81-88. PubMed ID: 27534574
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effectivity and safety of PD-1/PD-L1 inhibitors for different level of PD-L1-positive, advanced NSCLC: A meta-analysis of 4939 patients from randomized controlled trials.
    Shi Y; Duan J; Guan Q; Xue P; Zheng Y
    Int Immunopharmacol; 2020 Jul; 84():106452. PubMed ID: 32339922
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Recent advances and challenges of immune checkpoint inhibitors in immunotherapy of non-small cell lung cancer.
    Wu Z; Man S; Sun R; Li Z; Wu Y; Zuo D
    Int Immunopharmacol; 2020 Aug; 85():106613. PubMed ID: 32450531
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Separating or combining immune checkpoint inhibitors (ICIs) and radiotherapy in the treatment of NSCLC brain metastases.
    Li W; Yu H
    J Cancer Res Clin Oncol; 2020 Jan; 146(1):137-152. PubMed ID: 31813004
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Efficacy of PD-1/PD-L1 immune checkpoint inhibitors and PD-L1 testing in thoracic cancers].
    Duruisseaux M; Rouquette I; Adam J; Cortot A; Cazes A; Gibault L; Damotte D; Lantuejoul S
    Ann Pathol; 2017 Feb; 37(1):61-78. PubMed ID: 28162296
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Current status of immune checkpoint inhibitors in treatment of non-small cell lung cancer.
    Lim SW; Ahn MJ
    Korean J Intern Med; 2019 Jan; 34(1):50-59. PubMed ID: 30612418
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Non-small-cell lung cancer brain metastases and PD-(L)1 immune checkpoint inhibitors.
    Barlesi F; Tomasini P
    Lancet Oncol; 2020 May; 21(5):607-608. PubMed ID: 32251624
    [No Abstract]   [Full Text] [Related]  

  • 20. Efficacy and safety of immune checkpoint blockade for brain metastases.
    Harary M; Reardon DA; Iorgulescu JB
    CNS Oncol; 2019 Jun; 8(2):CNS33. PubMed ID: 30854898
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 32.